New combo therapy hopes to tame Slow-Growing blood cancer
NCT ID NCT07372365
First seen Jan 31, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests a new approach for people with a slow-growing lymphoma called marginal zone lymphoma (MZL). Participants first get a short course of standard chemo, then a targeted drug (Orelabrutinib) to keep the cancer under control. The goal is to see if this approach improves response rates and delays the cancer's return. About 23 people will take part, and they will be closely monitored for side effects and treatment success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA(MZL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.